In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report).

圣地亚哥 - 市值7.96亿美元的生命科学试剂和服务供应商Maravai LifeSciences, Inc. (NASDAQ: MRVI)宣布收购Molecular Assemblies, Inc.的知识产权和资产。根据 InvestingPro 数据，该公司保持强劲的流动性，流动比率为10.74，尽管面临近期挑战，过去十二个月收入下降34%。此次收购将增强Maravai子公司TriLink ...

TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has partnered with, ...

Justin Barbosa, GM and Vice President of TriLink Discovery, added “By integrating Molecular Assemblies technology into ...

北京时间2025年01月18日03时33分，Maravai Lifesciences Holdings, Inc.（MRVI.us）股票出现异动，股价急速上涨5.03%。截至发稿，该股报4.80 ...

EST Maravai Lifesciences (MRVI) jumps 6% to $5.85 after MAI IP acquisition announcementInvest with Confidence: Follow TipRanks' Top Wall ...

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) was the target of some unusual options trading on ...

SAN DIEGO - Maravai LifeSciences, Inc. (NASDAQ: MRVI), a $796 million market cap company known for supplying life science reagents and services, has announced the acquisition of intellectual ...

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases.

TriLink BioTechnologies, a Maravai LifeSciences company and provider of life science reagents and services, has partnered ...